LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

✍ Scribed by Schuler, Martin; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O’Byrne, Ken; Hirsh, Vera; Mok, Tony; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Sequist, Lecia

• Book ID: 119320860
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 53 KB
• Volume: 77
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/j.lungcan.2012.05.043